Homology Medicines Defeats Investor Suit Over Clinical Trial (1)

Homology Medicines Inc. investors failed to show the company made misleading statements about the progress of a virus-delivered gene therapy for phenylketonuria, a federal court ruled.

“Homology had no duty to disclose data in real time,” Judge Angel Kelley said in an opinion docketed Wednesday in the US District Court for the District of Massachusetts. The company’s disclosure of only some patient data from an early clinical trial was justified by “cutoff” dates in the study, Kelley said.

Further, most of the company’s statements about the data constituted a subjective interpretation, considered inactionable opinions, she said.

Other categories of challenged ...